ASCO features many updates on GIST trials. Promising results for the immunotherapy approach to treating cancer dominated the annual conference of the ASCO and represent one of the biggest developments in cancer research since the advent [...]
The American Society of Clinical Oncologists (ASCO) and Livestrong Foundation have launched a video on YouTube to promote discussion of fertility preservation in young cancer patients. Keep reading to learn more.
Here is an overview of what Jim Hughes, Pete Knox and Jerry Call learned at ASCO. There will be a more in depth article to come.
This is a brief summary of abstracts presented at the 2013 GI ASCO meeting. Please note that abstracts have not been through a complete peer review process and are considered to be preliminary.
Two posters were presented by principal investigators in the Phase 2 and 3 trials of masitinib for the treatment of newly diagnosed GIST patients.
By Jim Hughes Here are updates from the American Society of Clinical Oncology conference on three GIST clinical trials. Panobinostat (HDAC) Phase 1 in 3rd Line GIST: LRG research Team member Sebastian Bauer, MD of Essen University [...]
Trial investigators for the Global Phase 3 GRID trial reported that the Bayer Pharmaceuticals’ drug regorafenib (BAY 73-4506) has the potential to fill the unmet need for advanced GIST patients progressing after imatinib and sunitinib. [...]
One of the highlights of the American Society of Clinical Oncology (ASCO) conference was the session “Gastrointestinal Stromal Tumors: Multimodal Approach.” George Demetri M.D. began the discussion with a review of the history and biology of GIST. Dr. Demetri reviewed the current status of GIST and brought up some new challenges ahead.
This year’s American Society of Clinical Oncology conference (ASCO), held in Chicago in June, produced a number of interesting and informative GIST-relevant presentations. Below is an overview and we will be posting the rest of the articles very soon.
Results of the Scandinavian Sarcoma Group (SSG 18) adjuvant imatinib (Gleevec/Glivec) trial in high risk GIST were presented on June 5, during the Plenary Session of the 2011 American Society of Clinical Oncology conference (ASCO). The Plenary or “all members’ session” highlights “abstracts deemed to have the highest merit and greatest impact on oncology research and practice”.